SRHHYPOLTD Dividend 2026 | ₹3 Final Dividend | Record Date, Yield & Sustainability Analysis

Market Data

Sree Rayalaseema Hi-Strength Hypo Limited, part of the TGV Group, is India's only manufacturer of Calcium Hypochlorite and among very few globally. Incorporated in March 2005 and headquartered in Kurnool, Andhra Pradesh, the company produces industrial chemicals including sulphuric acid, chlorosulphonic acid, stable bleaching powder, sodium hydride, sodium methoxide, and water treatment chemicals.

The company operates through two segments: Chemicals (primary, over 90% of revenue) and Wind Energy – Power Generation. It also engages in coal trading. Sree Rayalaseema exports to multiple countries, with international revenue of ₹255.43 Crore in FY26 (38.3% of total revenue). Domestic revenue stood at ₹411.53 Crore. The company holds ISO 9001, 14001, and OHSAS 18001 certifications.

The company has a subsidiary – TGV Metals and Chemicals Private Limited – and holds a 22.31% stake in M V Salts & Chemicals Private Limited. Chairperson and Managing Director is Smt. T.G. Shilpa Bharath. The statutory auditor is S.T. Mohite & Co., who issued an unmodified (clean) opinion on both standalone and consolidated results.

Sree Rayalaseema Hi-Strength Hypo has maintained an unbroken dividend track record over the past decade, growing DPS from ₹1.50 in FY16 to ₹3.00 in FY26 — a CAGR of approximately 7%. The FY26 dividend of ₹3.00 is flat compared to FY25. The company reduced the dividend from ₹3.50 in FY23 to ₹3.00 in FY24, reflecting lower earnings. The payout ratio has consistently remained below 10%, indicating the company retains the vast majority of profits for growth and reserves. Classification: Consistent Payer with moderate growth.

The FY26 final dividend of ₹3.00 per share signals stability rather than growth. At a payout ratio of just 5.71%, Sree Rayalaseema retains ₹85 Crore of its ₹90 Crore profit for internal use. This is not a traditional dividend stock — it is primarily a capital appreciation play with a token dividend as a signal of financial health.

The real story lies in the company's ₹434 Crore cash pile (standalone) against a market cap of ₹994 Crore. Cash and investments together total approximately ₹741 Crore — representing nearly 75% of the market cap. The stock trades at just 1x book value and 10x earnings, suggesting either the market sees risks ahead or the company is deeply undervalued.

The ₹13.50 Crore exceptional loss (gold investment write-off and debenture derecognition) deserves scrutiny. Management deploying surplus cash into gold and debentures that subsequently lost value raises questions about capital allocation discipline. Shareholders should monitor whether these non-core investment losses become a recurring pattern.

Revenue growth turned positive in FY26 at +4.6% YoY after two years of decline (5-year revenue CAGR: -6%). The Q1 FY27 revenue of ₹211 Crore (up 17% YoY) suggests the recovery is accelerating. The chemicals segment benefits from steady demand for water treatment chemicals, bleaching powder, and calcium hypochlorite across domestic and export markets.

However, operating margins compressed to ~8% in Q4 FY26 from 15% in Q1 FY26, driven by higher material costs and other expenses. The company's ability to pass on input cost increases and maintain OPM above 12-13% will be critical for sustaining current earnings levels.

Given the conservative payout policy (sub-6%), dividends are likely to remain in the ₹3.00-3.50 range unless the company announces a special dividend or significantly changes its capital allocation framework. With ₹741 Crore in cash and investments sitting idle against a ₹994 Crore market cap, there is considerable scope for either increased dividends, buybacks, or expansion capex.

The Board of Directors of Sree Rayalaseema Hi-Strength Hypo Limited, at their meeting held on May 30, 2026, recommended a final dividend of ₹3.00 per equity share (30% on face value of ₹10) for FY2025-26 ended March 31, 2026. The dividend was subject to shareholder approval at the Annual General Meeting.

The 21st AGM was held on September 26, 2026, where shareholders approved the dividend. The Board also approved standalone and consolidated audited financial results for Q4 and full year FY26, reappointed Nirmal Kumar Reddy & Co. as Internal Auditor, and Santosh & Associates as Cost Auditor for FY2026-27.

The total dividend outflow is approximately ₹5.15 Crore distributed among 1,71,64,800 equity shares. This represents 5.71% of consolidated PAT of ₹90.15 Crore. The announcement was signed by V. Surekha, Sr. GM & Company Secretary.

Operating Leverage Analysis (Consolidated)

Key finding: Revenue grew 4.6% but operating profit declined 4.3%, indicating margin compression. Material costs rose 18.5% YoY to ₹331.82 Cr, growing faster than revenue. Employee costs surged 18.9% to ₹40.90 Cr (partly due to ₹6.86 Cr retrospective gratuity charge). PAT still grew 3.4% due to higher other income (₹54.79 Cr vs ₹39.47 Cr) offsetting weaker operational performance.

Consolidated Cash Flows (₹ Crore)

Funded through: Current earnings. The dividend of ₹5.15 Crore is comfortably covered by PAT of ₹90.15 Crore, FCF of ₹38 Crore, and a massive cash reserve. There is no evidence of the dividend being funded through borrowings or asset sales.

Debt position: Borrowings are declining (₹16 Cr in FY25 → ₹0.39 Cr in FY26). The company is not increasing debt to pay dividends.

Earnings trend: PAT grew 3.4% YoY. Revenue is recovering after two years of decline. Earnings remain positive and stable.

Sustainability Classification: SUSTAINABLE ✓

Sree Rayalaseema trades at a 57% discount to peer median P/E and a 49% discount on P/B. While this looks cheap, the discount partly reflects its small-cap nature (₹994 Cr market cap), low liquidity, and declining 5-year revenue CAGR of -6%. The dividend yield is below industry average due to the ultra-conservative payout policy, not a valuation issue. Among chemical manufacturers, the company's balance sheet strength and debt-free status are genuine competitive advantages.

Indian Dividend Tax Rules

Dividends are taxable in the hands of shareholders at their applicable income tax slab rate. Companies deduct TDS at 10% if dividend income exceeds ₹5,000 in a financial year. NRI shareholders face 20% TDS plus applicable surcharge and cess.

Worked Example: 1,000 Shares, 30% Tax Slab

TDS paid can be adjusted against total tax liability at the time of ITR filing. Effective yield after maximum tax is only 0.36%, making this unattractive for income-seeking investors in the highest tax bracket.

1. 1Revenue Cyclicality: 5-year revenue CAGR is -6%. The chemicals business is highly cyclical, and revenue dropped from ₹1,650 Crore (FY23) to ₹667 Crore (FY26) — a 60% decline in three years. Future revenue recovery is not guaranteed.
2. 2Cash Flow Quality Weakness: FY26 OCF/PAT ratio dropped to 43% from 177% in FY24. If cash flow quality continues deteriorating, even the small dividend could come under pressure despite strong paper profits.
3. 3Non-Core Investment Losses: ₹13.50 Crore in exceptional losses from gold and debenture investments indicates treasury management risk. The company holds ₹307 Crore in investments — further mark-to-market losses are possible.
4. 4Margin Compression: Q4 FY26 OPM fell to ~8% from 15% in Q1. Raw material cost inflation, higher employee costs (new labour code), and other expenses are squeezing margins. This may impact future earnings.
5. 5Export Concentration Risk: International revenue declined from ₹285.94 Cr (FY25) to ₹255.43 Cr (FY26), a 10.7% drop. Global trade disruptions (the Maersk shipping litigation is an example) and currency volatility can materially impact the export business.
6. 6Low Liquidity: With negligible FII (0.06%) and DII (0.05%) ownership and small-cap status, the stock has low trading liquidity, making it vulnerable to sharp price moves and difficult to exit during market stress.
7. 7Capital Allocation Concern: ₹741 Crore in cash and investments (75% of market cap) sitting idle suggests sub-optimal capital deployment. The company could be earning better returns through expansion, buybacks, or higher dividends rather than accumulating treasury assets.

1. 1OCF/PAT Recovery: The 43% OCF/PAT ratio in FY26 is a critical red flag. Monitor whether FY27 quarterly cash flows show improvement back towards 80-100% conversion.
2. 2Operating Margin Trajectory: Track quarterly OPM — if it consistently stays below 12%, the revenue recovery is not translating to profitability improvement.
3. 3Revenue Recovery Momentum: Q1 FY27 showed ₹211 Cr revenue (+17% YoY). Watch if this trajectory sustains across Q2-Q4, especially export revenue which declined in FY26.
4. 4Investment Portfolio Performance: The ₹307 Crore investment portfolio generated ₹13.50 Crore in exceptional losses in FY26. Track whether management reduces non-core investments or whether further mark-to-market losses emerge.
5. 5Capital Allocation Announcements: Any announcement of capacity expansion, buyback, special dividend, or strategic acquisition from the ₹741 Crore cash pile would be a significant catalyst.
6. 6Promoter Holding Stability: Promoters hold a stable 61.84% with zero pledge. Any change in promoter holding direction would be significant for the investment thesis.
7. 7Maersk Litigation Outcome: The UK commercial court proceedings initiated by Maersk Shipping Line could have financial implications. Monitor corporate announcements for updates.

Sree Rayalaseema Hi-Strength Hypo Limited's ₹3.00 final dividend for FY26 is a sustainable but modest payout from a financially strong company. At a 5.71% payout ratio, 17.75x earnings coverage, and ₹741 Crore cash pile, the dividend is among the safest on the market — but the yield of 0.52% is too low for income investors.

Positives: Debt-free balance sheet, consistent dividend track record (10+ years), massive cash reserves, stock trading below book value (P/B ~1.0x), revenue recovery in progress, and unmodified audit opinion.

Negatives: Deteriorating cash flow quality (OCF/PAT at 43%), margin compression in Q4, exceptional investment losses (₹13.50 Cr), 5-year revenue CAGR of -6%, ultra-low dividend yield, negligible institutional interest, and sub-optimal capital allocation with excess cash earning modest returns.

The investment case hinges on whether you believe the company will eventually deploy its ₹741 Crore cash hoard productively — through expansion, acquisitions, buybacks, or substantially higher dividends — or continue letting it accumulate at low returns. At 10x earnings with a fortress balance sheet, the margin of safety exists, but catalysts for re-rating remain uncertain.